The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| VTRS | -9.38% | -30.15% | -6.92% | +2,357% |
| S&P | +19.61% | +98.99% | +14.75% | +4,237% |
Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.
Viatris reported mixed results for Q4 2024, missing revenue and EPS expectations, despite noteworthy debt reduction and portfolio adjustments.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $3.58B | -5.4% |
| Gross Profit | $1.41B | -2.8% |
| Gross Margin | 39.28% | 1.1% |
| Market Cap | $3.11B | -17.2% |
| Market Cap / Employee | $0.10M | 0.0% |
| Employees | 32K | -15.8% |
| Net Income | -$4.60M | 98.6% |
| EBITDA | $1.04B | 32.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $567.80M | -38.2% |
| Accounts Receivable | $2.79B | 4.1% |
| Inventory | 4.3K | 8.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $12.97B | -13.1% |
| Short Term Debt | $1.79B | -27.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -8.28% | -6.9% |
| Return On Invested Capital | -0.22% | -0.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $166.80M | -47.9% |
| Operating Free Cash Flow | $219.70M | -42.0% |
| Metric | Q4 2023 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 255.42 | - | |||
| Price to Book | 0.21 | 0.22 | 0.17 | 0.20 | 5.30% |
| Price to Sales | 0.93 | 1.01 | 0.73 | 0.75 | -10.59% |
| Price to Tangible Book Value | -0.53 | -0.57 | -0.41 | -0.42 | -2.89% |
| Price to Free Cash Flow TTM | 10.15 | 10.60 | 7.81 | 8.86 | -4.73% |
| Enterprise Value to EBITDA | 24.14 | 31.44 | 28.52 | 23.67 | -35.92% |
| Free Cash Flow Yield | 9.9% | 9.4% | 12.8% | 11.3% | 4.97% |
| Return on Equity | -4.3% | -3.2% | -21.3% | -19.8% | 517.09% |
| Total Debt | $16.02B | $14.31B | $14.47B | $14.77B | -15.04% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
